{
    "info": {
        "nct_id": "NCT02849990",
        "official_title": "A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy",
        "inclusion_criteria": "* Willing and able to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* Documented histologically confirmed adenocarcinoma of the prostate\n* Willing to undergo prostatectomy as primary treatment for localized prostate cancer\n* High risk prostate cancer (per National Comprehensive Cancer Network [NCCN] criteria): Gleason score 8-10 or T3a or PSA > 20 ng/mL or very-high risk prostate cancer (per NCCN criteria): T3b-T4\n* Serum testosterone >= 150 ng/dL\n* Able to swallow the study drugs whole\n* Willing to take abiraterone acetate on an empty stomach (no food should be consumed at least two hours before and for one hour after dosing)\n* Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug\n* Medications known to lower the seizure threshold (see list under prohibited meds) must be discontinued or substituted at least 4 weeks prior to study entry\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy)\n* Prior use of apalutamide, abiraterone acetate or degarelix\n* Prior or ongoing systemic therapy for prostate cancer including, but not limited to:\n\n  * Hormonal therapy (for example [e.g.] leuprolide, goserelin, triptorelin, degarelix)\n  * Cytochrome P450 (CYP)-17 inhibitors (e.g. ketoconazole)\n  * Antiandrogens (e.g. bicalutamide, nilutamide)\n  * Second generation antiandrogens (e.g. enzalutamide, apalutamide)\n  * Immunotherapy (e.g. sipuleucel-T, ipilimumab)\n  * Chemotherapy (e.g. docetaxel, cabazitaxel)\n* Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study\n* Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule\n* Absolute neutrophil count [ANC] < 1500/mm^3\n* Platelet count < 100,000/mm^3\n* Hemoglobin < 9 g/dL\n* Total bilirubin > 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN; Note: in subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be eligible\n* Abnormal kidney function (glomerular filtration rate GFR < 45 mL/min)\n* Serum albumin < 3 g/dL\n* Serum potassium < 3.5 mmol/L\n* Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year to randomization, brain arteriovenous malformation, schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy)\n* Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization\n* History of stroke within the last 5-years\n* History of gastrointestinal (GI) bleed requiring transfusion\n* History of peptic ulcer disease requiring treatment within the last 5-years\n* History of asthma that is nonsteroidal anti-inflammatory drug (NSAID)-induced or with asthma that is classified as 'mild-persistent' or worse (based on symptoms occurring more than 2 days per week)\n* Uncontrolled hypertension\n* Gastrointestinal disorder affecting absorption\n* Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)\n* Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/ prednisolone once daily\n* Any condition that in the opinion of the investigator, would preclude participation in this study\n* Child Pugh class B & C\n* Pre-existing viral hepatitis",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented histologically confirmed adenocarcinoma of the prostate",
            "criterions": [
                {
                    "exact_snippets": "Documented histologically confirmed adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High risk prostate cancer (per National Comprehensive Cancer Network [NCCN] criteria): Gleason score 8-10 or T3a or PSA > 20 ng/mL or very-high risk prostate cancer (per NCCN criteria): T3b-T4",
            "criterions": [
                {
                    "exact_snippets": "Gleason score 8-10",
                    "criterion": "Gleason score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "T3a",
                    "criterion": "tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "T3a"
                        }
                    ]
                },
                {
                    "exact_snippets": "PSA > 20 ng/mL",
                    "criterion": "prostate-specific antigen (PSA) level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "ng/mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "T3b-T4",
                    "criterion": "tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "T3b",
                                "T4"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing and able to provide written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Willing and able to provide written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum testosterone >= 150 ng/dL",
            "criterions": [
                {
                    "exact_snippets": "Serum testosterone >= 150 ng/dL",
                    "criterion": "serum testosterone",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to take abiraterone acetate on an empty stomach (no food should be consumed at least two hours before and for one hour after dosing)",
            "criterions": [
                {
                    "exact_snippets": "Willing to take abiraterone acetate",
                    "criterion": "abiraterone acetate administration",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on an empty stomach (no food should be consumed at least two hours before and for one hour after dosing)",
                    "criterion": "abiraterone acetate administration timing relative to food",
                    "requirements": [
                        {
                            "requirement_type": "fasting period before dosing",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "hours"
                            }
                        },
                        {
                            "requirement_type": "fasting period after dosing",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "hour"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential",
                    "criterion": "contraceptive use during sex with woman of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use condom",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agreement to use another effective method of birth control",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug",
                    "criterion": "condom use during sex with pregnant woman",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use condom",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during study drug"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "agreement not to donate sperm",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Medications known to lower the seizure threshold (see list under prohibited meds) must be discontinued or substituted at least 4 weeks prior to study entry",
            "criterions": [
                {
                    "exact_snippets": "Medications known to lower the seizure threshold ... must be discontinued or substituted at least 4 weeks prior to study entry",
                    "criterion": "use of medications known to lower the seizure threshold",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation or substitution",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks prior to study entry"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to swallow the study drugs whole",
            "criterions": [
                {
                    "exact_snippets": "Able to swallow the study drugs whole",
                    "criterion": "ability to swallow study drugs whole",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to undergo prostatectomy as primary treatment for localized prostate cancer",
            "criterions": [
                {
                    "exact_snippets": "Willing to undergo prostatectomy as primary treatment",
                    "criterion": "willingness to undergo prostatectomy",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "localized prostate cancer",
                    "criterion": "prostate cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "localized"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
            "criterions": [
                {
                    "exact_snippets": "Any psychological ... condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                    "criterion": "psychological condition",
                    "requirements": [
                        {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any ... familial ... condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                    "criterion": "familial condition",
                    "requirements": [
                        {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any ... sociological ... condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                    "criterion": "sociological condition",
                    "requirements": [
                        {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any ... geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                    "criterion": "geographical condition",
                    "requirements": [
                        {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy)",
            "criterions": [
                {
                    "exact_snippets": "Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy)",
                    "criterion": "prior local therapy for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of asthma that is nonsteroidal anti-inflammatory drug (NSAID)-induced or with asthma that is classified as 'mild-persistent' or worse (based on symptoms occurring more than 2 days per week)",
            "criterions": [
                {
                    "exact_snippets": "History of asthma that is nonsteroidal anti-inflammatory drug (NSAID)-induced",
                    "criterion": "asthma",
                    "requirements": [
                        {
                            "requirement_type": "induced_by_NSAID",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "asthma that is classified as 'mild-persistent' or worse (based on symptoms occurring more than 2 days per week)",
                    "criterion": "asthma severity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "mild-persistent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Severe or unstable angina ... within 6 months prior to randomization",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "severe",
                                "unstable"
                            ]
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction ... within 6 months prior to randomization",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure ... within 6 months prior to randomization",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks) ... within 6 months prior to randomization",
                    "criterion": "thromboembolic events",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "arterial",
                                "venous"
                            ]
                        },
                        {
                            "requirement_type": "examples",
                            "expected_value": [
                                "pulmonary embolism",
                                "cerebrovascular accident",
                                "transient ischemic attacks"
                            ]
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant ventricular arrhythmias within 6 months prior to randomization",
                    "criterion": "ventricular arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count [ANC] < 1500/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count [ANC] < 1500/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1500,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pre-existing viral hepatitis",
            "criterions": [
                {
                    "exact_snippets": "Pre-existing viral hepatitis",
                    "criterion": "viral hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "pre-existing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Child Pugh class B & C",
            "criterions": [
                {
                    "exact_snippets": "Child Pugh class B & C",
                    "criterion": "Child Pugh class",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of stroke within the last 5-years",
            "criterions": [
                {
                    "exact_snippets": "History of stroke within the last 5-years",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Antiandrogens (e.g. bicalutamide, nilutamide)",
            "criterions": [
                {
                    "exact_snippets": "Antiandrogens (e.g. bicalutamide, nilutamide)",
                    "criterion": "antiandrogen use",
                    "requirements": [
                        {
                            "requirement_type": "use or exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum albumin < 3 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Serum albumin < 3 g/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin < 9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin < 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any condition that in the opinion of the investigator, would preclude participation in this study",
            "criterions": [
                {
                    "exact_snippets": "Any condition that in the opinion of the investigator, would preclude participation in this study",
                    "criterion": "any condition precluding participation (per investigator judgment)",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": "would preclude participation in this study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum potassium < 3.5 mmol/L",
            "criterions": [
                {
                    "exact_snippets": "Serum potassium < 3.5 mmol/L",
                    "criterion": "serum potassium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.5,
                                "unit": "mmol/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Abnormal kidney function (glomerular filtration rate GFR < 45 mL/min)",
            "criterions": [
                {
                    "exact_snippets": "Abnormal kidney function (glomerular filtration rate GFR < 45 mL/min)",
                    "criterion": "kidney function (glomerular filtration rate)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study",
            "criterions": [
                {
                    "exact_snippets": "Evidence of serious and/or unstable pre-existing medical ... condition",
                    "criterion": "pre-existing medical condition",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "serious and/or unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "Evidence of serious and/or unstable pre-existing ... psychiatric ... condition",
                    "criterion": "pre-existing psychiatric condition",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "serious and/or unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "Evidence of serious and/or unstable pre-existing ... other condition",
                    "criterion": "pre-existing other condition",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "serious and/or unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "(including laboratory abnormalities)",
                    "criterion": "laboratory abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin > 1.5 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin > 1.5 x upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)",
            "criterions": [
                {
                    "exact_snippets": "Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cytochrome P450 (CYP)-17 inhibitors (e.g. ketoconazole)",
            "criterions": [
                {
                    "exact_snippets": "Cytochrome P450 (CYP)-17 inhibitors (e.g. ketoconazole)",
                    "criterion": "CYP-17 inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior or ongoing systemic therapy for prostate cancer including, but not limited to:",
            "criterions": [
                {
                    "exact_snippets": "Prior or ongoing systemic therapy for prostate cancer",
                    "criterion": "systemic therapy for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunotherapy (e.g. sipuleucel-T, ipilimumab)",
            "criterions": [
                {
                    "exact_snippets": "Immunotherapy (e.g. sipuleucel-T, ipilimumab)",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "received immunotherapy (e.g. sipuleucel-T, ipilimumab)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Second generation antiandrogens (e.g. enzalutamide, apalutamide)",
            "criterions": [
                {
                    "exact_snippets": "Second generation antiandrogens (e.g. enzalutamide, apalutamide)",
                    "criterion": "second generation antiandrogen use",
                    "requirements": [
                        {
                            "requirement_type": "use or exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hormonal therapy (for example [e.g.] leuprolide, goserelin, triptorelin, degarelix)",
            "criterions": [
                {
                    "exact_snippets": "Hormonal therapy (for example [e.g.] leuprolide, goserelin, triptorelin, degarelix)",
                    "criterion": "hormonal therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "leuprolide",
                                "goserelin",
                                "triptorelin",
                                "degarelix"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year to randomization, brain arteriovenous malformation, schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy)",
            "criterions": [
                {
                    "exact_snippets": "Seizure",
                    "criterion": "seizure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known condition that may pre-dispose to seizure",
                    "criterion": "condition predisposing to seizure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior stroke within 1 year to randomization",
                    "criterion": "prior stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "brain arteriovenous malformation",
                    "criterion": "brain arteriovenous malformation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "schwannoma",
                    "criterion": "schwannoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "meningioma",
                    "criterion": "meningioma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy",
                    "criterion": "benign CNS or meningeal disease requiring surgery or radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "potential need for surgery or radiation therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/ prednisolone once daily",
            "criterions": [
                {
                    "exact_snippets": "Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/ prednisolone once daily",
                    "criterion": "chronic medical condition",
                    "requirements": [
                        {
                            "requirement_type": "corticosteroid dose requirement",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone/prednisolone once daily"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN; Note: in subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be eligible",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... >= 2.5 x ULN",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) >= 2.5 x ULN",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN",
                    "criterion": "total bilirubin (in subjects with Gilbert's syndrome)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be eligible",
                    "criterion": "direct bilirubin (in subjects with Gilbert's syndrome and total bilirubin > 1.5 x ULN)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count < 100,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Platelet count < 100,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gastrointestinal disorder affecting absorption",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal disorder affecting absorption",
                    "criterion": "gastrointestinal disorder",
                    "requirements": [
                        {
                            "requirement_type": "affecting absorption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior use of apalutamide, abiraterone acetate or degarelix",
            "criterions": [
                {
                    "exact_snippets": "Prior use of apalutamide",
                    "criterion": "apalutamide use",
                    "requirements": [
                        {
                            "requirement_type": "prior use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior use of ... abiraterone acetate",
                    "criterion": "abiraterone acetate use",
                    "requirements": [
                        {
                            "requirement_type": "prior use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior use of ... degarelix",
                    "criterion": "degarelix use",
                    "requirements": [
                        {
                            "requirement_type": "prior use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of gastrointestinal (GI) bleed requiring transfusion",
            "criterions": [
                {
                    "exact_snippets": "History of gastrointestinal (GI) bleed requiring transfusion",
                    "criterion": "gastrointestinal (GI) bleed",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "requiring transfusion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy (e.g. docetaxel, cabazitaxel)",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy (e.g. docetaxel, cabazitaxel)",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "chemotherapy (e.g. docetaxel, cabazitaxel)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of peptic ulcer disease requiring treatment within the last 5-years",
            "criterions": [
                {
                    "exact_snippets": "History of peptic ulcer disease requiring treatment within the last 5-years",
                    "criterion": "peptic ulcer disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}